Skip to main content
Search
section
Global
Digital
ESG
Media Center
Careers
Language & Country Selector for Desktop
Global
|
en
Choose Location
International
Americas
Europe
Middle East & Africa
Asia Pacific
Global |
en
Sandoz |
en
Novartis Foundation |
en
Argentina |
es
Brazil |
pt
Canada |
en
Canada |
fr
Central America |
es
Colombia |
es
Mexico |
es
United States |
en
Venezuela |
es
Austria |
de
Belgium |
fr
Belgium |
nl
Bulgaria |
bg
Czech Republic |
cs
Czech Republic |
en
Denmark |
da
Estonia |
et
Finland |
fi
France |
fr
Germany |
de
Greece |
el
Hungary |
hu
Ireland |
en
Italy |
it
Latvia |
lv
Lithuania |
lt
Netherlands |
nl
Norway |
no
Poland |
pl
Portugal |
pt
Romania |
ro
Russia |
ru
Serbia |
sr
Slovakia |
sk
Spain |
es
Sweden |
sv
Switzerland |
de
Switzerland |
fr
United Kingdom |
en
Egypt |
en
Israel |
he
South Africa |
en
Turkey |
tr
Australia |
en
Bangladesh |
en
Hong Kong S.A.R. |
zh
India |
en
Indonesia |
en
Japan |
ja
Korea |
ko
Mainland China |
zh
Malaysia |
en
Pakistan |
en
Philippines |
en
Singapore |
en
Taiwan |
zh
Language & Country Selector for Mobile
Global
Choose Location
International
International
Americas
Europe
Middle East & Africa
Asia Pacific
Argentina |
es
Australia |
en
Austria |
de
Bangladesh |
en
Belgium |
fr
Belgium |
nl
Brazil |
pt
Bulgaria |
bg
Canada |
en
Canada |
fr
Central America |
es
Colombia |
es
Czech Republic |
cs
Czech Republic |
en
Denmark |
da
Egypt |
en
Estonia |
et
Finland |
fi
France |
fr
Germany |
de
Greece |
el
Hong Kong S.A.R. |
zh
Hungary |
hu
India |
en
Indonesia |
en
Ireland |
en
Israel |
he
Italy |
it
Japan |
ja
Korea |
ko
Latvia |
lv
Lithuania |
lt
Mainland China |
zh
Malaysia |
en
Mexico |
es
Netherlands |
nl
Norway |
no
Global |
en
Sandoz |
en
Novartis Foundation |
en
Pakistan |
en
Philippines |
en
Poland |
pl
Portugal |
pt
Romania |
ro
Russia |
ru
Serbia |
sr
Singapore |
en
Slovakia |
sk
South Africa |
en
Spain |
es
Sweden |
sv
Switzerland |
de
Switzerland |
fr
Taiwan |
zh
Turkey |
tr
United Kingdom |
en
United States |
en
Venezuela |
es
Menu
About
Board of Directors
Joerg Reinhardt
Simon Moroney
Nancy Andrews
Ton Buechner
Patrice Bula
Elizabeth Doherty
Ana de Pro Gonzalo
Bridgette Heller
Daniel Hochstrasser
Frans van Houten
Andreas von Planta
Charles Sawyers
William Winters
Charlotte Pamer-Wieser
Executive Committee
Vasant Narasimhan
Shreeram Aradhye
James Bradner
Victor Bulto
Karen Hale
Harry Kirsch
Rob Kowalski
Steffen Lang
Klaus Moosmayer
Richard Saynor
Marie-France Tschudin
Lutz Hegemann
Michael Willi
Kees Roks
Strategy
People and Culture
Data and Digital
Products
Innovative Medicines
Sandoz
Operations
Global Biotech Cooperations
Diversity & Inclusion
Equity
Diversity & Inclusion Governance and Community
Inclusivity
Parental Leave
Society
Quality
Audit program
Novartis Quality Management System (QMS)
Product and patient safety training
Regulatory inspections
Product recalls
Third-party suppliers
About Novartis
Patients and Caregivers
Novartis Commitment to Patients and Caregivers
Diseases
Patient Organization Funding
Adverse Event Reporting
COVID-19: Patients and Caregivers
Stories: Patients Perspectives
Patients & Caregivers
Healthcare Professionals
Medical Congresses and Events
Abstract summaries for EULAR
Abstract summaries for ACR
Abstract summaries for EADV
Products
Novartis Pipeline
Managed Access Programs
Novartis Gene Therapies Managed Access Program
Novartis External Funding
Healthcare Professional Resources by Country
Investigator-Initiated Trials / Studies
Transparency and Disclosure
Novartis Medical Information
Submit medical enquiry
Healthcare Professionals
Research & Development
Novartis Institutes for BioMedical Research
Collaborations
NIBR Global Scholars Program
Technology Platforms
Radioligand Therapy
Gene Therapy
Cell Therapy
Research Disease Areas
Immuno-oncology research at Novartis
Oncology research at Novartis
Cardiovascular and metabolic disease research at Novartis
Autoimmunity, transplantation and inflammatory disease research at Novartis
Ophthalmology research at Novartis
Neuroscience Research at Novartis
Musculoskeletal Disease Research at Novartis
DAx: exploratory disease research at Novartis
Research Locations
Novartis Institute for Tropical Diseases
Novartis Pipeline
Translational Medicine
Research & Development Approach
Stories from our Labs
Open Source Science
Research & Development
ESG
Access
Creating sustainable business models
Value-Based Pricing
Sub-Saharan Africa
Donations
Novartis Access Principles
Novartis Oncology Access
Patents and Licensing
Ethics, Risk and Compliance
Ethical Behavior
Compliance
Human Rights
Learning and Engagement
Risk management
Environmental Sustainability
Climate
Waste
Water
Global Health
Anti-Microbial Resistance (AMR)
Avoidable Blindness
Chagas Disease
Leprosy
Malaria
Sickle Cell Disease (SCD)
Novartis Foundation
Diversity & Inclusion
Reporting
Environmental, Social and Governance (ESG) Index
ESG Rating Performance
Codes, Policies and Guidelines
Materiality Assessment
Transparency and Disclosure
Targets
Positions
Environmental, Social and Governance
Investors
Event Calendar
Financial Data
Novartis Annual Results
Novartis Quarterly Results
Novartis SEC Filings
Product Sales
Fixed-Income Securities
Expected Currency Impact
Share Data & Analysis
Share Monitor
Dividend Information
Share Ownership
Share Overview
Shareholder Information
General Meetings
American Depository Receipts (ADR)
Share Buy-Back
Frequently Asked Questions
Company Overview
Corporate Governance
Novartis Annual Reporting Suite
Reporting Archive
Publications Order Form
ESG
Investors
News
News Archive
Media Library
Stories
Subscribe
News
Careers
Career Search
Our Teams
Careers in Commercial
Careers in Communications and Advocacy
Careers in Consulting
Careers in Digital
Careers in Health, Safety & Environment
Careers in Information Technology (IT)
Careers in Medical & Development
Careers in People & Organization
Careers in Procurement
Careers in Research
Careers in Strategy
Careers in Manufacturing and Supply
Ethics, Risk & Compliance (ERC)
Careers in Legal
Career Programs
Community Exploration & Learning Lab (CELL)
Early Talent
Postdoc Program
Andreas Bender, PhD
Boxun Lu, PhD
The Novartis Innovation Postdoctoral Fellowship
The Novartis Discovery Postdoctoral Fellowship
Postdoc Research Themes
Recognition
Postdoc Program Leadership
International Careers
Learning and Development
Well-being
Internship Programs
Careers
COVID-19 Information Center
COVID-19 Novartis response
Clinical Trials
Clinical Trials
Partnering
Partnering
Contacts
Contacts
Home
Header
News Archive
Previous
Next
Home
News
News Archive
Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
- Any -
In The News
Media Release
Featured News
Story
Is This Statement?
- Any -
True
False
News Type Filters
Language
- Any -
English
German
French
News Archive Navigation
All
Key Releases
Media Releases
Featured News
In the News
Statements
Stories
Pulse Updates
icon
List View
News Archive Navigation Language
Language
English
German
French
June 2022
Statement
Jun 01, 2022
Novartis resumes business in Ukraine
May 2022
Featured News
May 23, 2022
Novartis at ASCO and EHA 2022
April 2022
Featured News
Apr 26, 2022
Novartis Financial Results – Q1 2022
Statement
Apr 19, 2022
Novartis provides more than USD 25 million in medical aid to patients in Ukraine and bordering countries
March 2022
Statement
Mar 22, 2022
Novartis condemns the war in Ukraine - update March 22
Statement
Mar 18, 2022
COVID-19 news feed
Statement
Mar 08, 2022
Novartis expands humanitarian efforts in Ukraine through donation of essential medicines
Statement
Mar 04, 2022
Novartis condemns the war in Ukraine and commits to supporting humanitarian efforts
February 2022
Statement
Feb 15, 2022
Novartis announces European Patent Office orders grant of the European Gilenya® (fingolimod) 0.5mg daily dose patent
Featured News
Feb 08, 2022
Novartis Co-Creating Impact Summit 2021
Featured News
Feb 02, 2022
Novartis 2021 Financial Results
January 2022
Statement
Jan 24, 2022
2021 Global Managed Access Program Community Update
Pagination
1
2
3
4
5
6
7
8
9
…
›
Next page
